Skip to content
Research Article Open access CC BY 4.0

Emergence of Third Generation Tetracyclines: New Magic Bullets to Tackle Antibiotic Resistance in the Post-antibiotic Era

Pranitha Jetty, Soni Gaddam, Satyanarayana S. V. Padi

Asian Journal of Research in Infectious Diseases · pp. 1–14 · Published 13 Jun 2023

10.9734/ajrid/2023/v13i4271

Abstract

Tetracyclines are broad-spectrum antibiotics effective against a wide variety of microorganisms including bacteria, both Gram-positive and Gram-negative, mycoplasmas, rickettsiae, chlamydiae, and protozoan parasites. Owing to their broad-spectrum antimicrobial activities and inexpensiveness, tetracyclines have been used extensively in both human and animal infections and in animal feed as growth promoters. Owing to this, the global prevalence of antibiotic resistance, particularly of tetracyclines, for Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae and Gram-negative extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species is high. Indeed, the acquisition of tetracycline-specific resistance genes, mutations within the ribosomal binding site, and/or chromosomal mutations lead to both class-specific and intrinsic antimicrobial resistance (AMR) mechanisms. As drug resistance increases globally, rendering diseases difficult to manage and eventually to mortality, antibiotics are becoming progressively less effective. Therefore, the discovery and development of novel antibiotics with appropriate indications is of the utmost importance. Among all antibiotics, the tetracyclines have acquired much attention due to the optimization of their chemical structures that paved the way to develop and introduce modern tetracyclines, referred to as third generation, namely tigecycline in the recent past, followed by omadacycline, eravacycline, and sarecycline very recently. Intriguingly, these novel tetracyclines are unique in two ways, first, these are highly effective against pathogens that acquired tetracycline-class resistance, and second, these agents exhibit either narrow or broad spectrum of in vitro activity against Gram-positive, Gram-negative, anaerobic, and atypical pathogens, including many drug-resistant strains lead to approval for limited use and unique indications. These beneficial effects represent a new era in the rational use of newer tetracyclines, the new magic bullets to tackle AMR in the post-antibiotic era. The present review focuses on third-generation tetracyclines emphasizing their safety, efficacy, and therapeutic choices in various clinical conditions of in-patient and out-patient settings.

Antimicrobial resistance eravacycline multidrug resistance omadacycline sarecycline tigecycline tetracyclines third generation

References (52)

  1. 1 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance [DOI]
  2. 2 Global increase and geographic convergence in antibiotic consumption between 2000 and 2015 [DOI]
  3. 3 Tackling drug-resistant infections globally: final report and recommendations
  4. 4 Antibiotics: past, present and future [DOI]
  5. 5 Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects [DOI]
  6. 6 A Review on Antibiotic Resistance: Alarm Bells are Ringing [DOI]
  7. 7 New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives [DOI]
  8. 8 Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data [DOI]
  9. 9 Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review [DOI]
  10. 10 Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review [DOI]
  11. 11 The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later [DOI]
  12. 12 Efficacy and safety of tigecycline: a systematic review and meta-analysis [DOI]
  13. 13 The Development of Third-Generation Tetracycline Antibiotics and New Perspectives [DOI]
  14. 14 Tetracycline-Inactivating Enzymes [DOI]
  15. 15 India's National Action Plan for antimicrobial resistance – An overview of the context, status, and way ahead [DOI]
  16. 16 Secondary Infections in Hospitalized COVID-19 Patients: Indian Experience [DOI]
  17. 17 Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance [DOI]
  18. 18 Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms [DOI]
  19. 19 Minocycline prevents the development of neuropathic pain, but not acute pain: Possible anti-inflammatory and antioxidant mechanisms [DOI]
  20. 20 Eravacycline: A Review in Complicated Intra-Abdominal Infections [DOI]
  21. 21 Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic [DOI]
  22. 22 An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria [DOI]
  23. 23 Why Do Antibiotics Exist? [DOI]
  24. 24 Tetracycline antibiotics [DOI]
  25. 25 Imagining a post-antibiotic era: a cultural analysis of crisis and antibiotic resistance [DOI]
  26. 26 The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline [DOI]
  27. 27 Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris [DOI]
  28. 28 Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting [DOI]
  29. 29 Omadacycline: A Modernized Tetracycline [DOI]
  30. 30 Sarecycline: First Global Approval [DOI]
  31. 31 Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease [DOI]
  32. 32 Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study.
  33. 33 From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term ‘complement’ [DOI]
  34. 34 The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis [DOI]
  35. 35 Sarecycline: A Review of Preclinical and Clinical Evidence [DOI]
  36. 36 Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity [DOI]
  37. 37 Tigecycline – how powerful is it in the fight against antibiotic-resistant bacteria? [DOI]
  38. 38 Efficacy and safety of eravacycline: A meta-analysis [DOI]
  39. 39 Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use [DOI]
  40. 40 Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs [DOI]
  41. 41 Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study [DOI]
  42. 42 An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris [DOI]
  43. 43 Antibiotic Prescribing Practices in Primary Care Settings Using 2019 WHO AWaRe Framework [DOI]
  44. 44 Eravacycline for the treatment of complicated intra‐abdominal infections [DOI]
  45. 45 Hospital Antibiotic Prescribing Pattern in General Surgery Specialty: Analysis Based on the WHO Access, Watch and Reserve (AWaRe) Classification [DOI]
  46. 46 Antibiotic Prescribing Practice in Chronic Kidney Disease Patients in a Tertiary Care Teaching Hospital: Analysis Based on 2019 WHO AWaRe Classification [DOI]
  47. 47 SARECYCLINE AND THE NARROW-SPECTRUM TETRACYCLINE CONCEPT: Currently Available Data and Potential Clinical Relevance in Dermatology.
  48. 48 Tigecycline: pharmacological concerns and resistance [DOI]
  49. 49 Tetracycline Antibiotics and Resistance [DOI]
  50. 50 Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism [DOI]
  51. 51 Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis [DOI]
  52. 52 Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis [DOI]

Cited by 12

Drug Repurposing for COVID-19: Current Status of Potential Therapeutics

Pravalika Avirineni, Sudheer K. Dundigalla, Satyanarayana S. V. Padi · Journal of Advances in Medical and Pharmaceutical Sciences · 2023

Biochar-derived photocatalysts for pharmaceutical waste removal, a sustainable approach to water purification

Maryam Zahid, Zia Ul Haq Khan, Jingyu Sun · Applied Surface Science Advances · 2025

Complexity of antibiotic resistance and its impact on gut microbiota dynamics

H. Shayista, M.N. Nagendra Prasad, S. Niranjan Raj · Engineering Microbiology · 2025

Newly Streptomyces-Induced Rabelomycin after Specific Amino Acid Supplementations: Experimental and Computational Investigations of Reactivities

Samira Tata, Nour El Houda Bensiradj, Amine Yekkour · Waste and Biomass Valorization · 2024

Showing 4 of 12 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

57

Page views

0

PDF downloads

28

Outbound clicks

12

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.